comparemela.com

Latest Breaking News On - James sidoti - Page 1 : comparemela.com

LeMaitre Vascular, Inc (NASDAQ:LMAT) Q4 2023 Earnings Call Transcript

LeMaitre Vascular, Inc. beats earnings expectations. Reported EPS is $0.38, expectations were $0.36. LeMaitre Vascular, Inc.

United statesKrung thep mahanakhonBruxelles capitaleSoult ukpyolsiSouth koreaFrance generalMichael petuskyDaniel stauderSuraj kaliaAsia pacDave robertsJames sidotiGeorge lemaitreRick wiseLemaitre vascularBarrington research

Varex Imaging Corporation (NASDAQ:VREX) Q4 2023 Earnings Call Transcript

Operator: Greetings, and welcome to the Varex Fourth Quarter and Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.

United statesSam maheshwariChristopher belfioreJames sidotiVarex imaging corporationSidoti companyMevis medical solutionsVarex imaging corpCall transcript novemberImaging corporationVarex fourth quarterFiscal yearSunny sanyalRisk factorsAnnual reportMevis liver

Surmodics, Inc (NASDAQ:SRDX) Q1 2023 Earnings Call Transcript

Operator: Welcome everyone to Surmodics First Quarter of Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.

Ramon varcoeMike matsonMichael matsonJames sidotiMike petuskyGary maharajTim arensSurmodics incNeedham companyValue analysis committeeSidoti companyBarrington researchInternational symposium on endovascular therapyCompany representativesCall transcript februaryChief executive officer tim arens

LeMaitre Vascular, Inc (LMAT) Q3 2022 Earnings Call Transcript

LeMaitre Vascular, Inc. (NASDAQ:NASDAQ:LMAT) Q3 2022 Results Conference Call October 27, 2022 05:00 PM ET Company Participants J.J.

New zealandUnited kingdomJavier fonsecaMatt mishanJim sidotiGeorge lemaitreDave robertsRick wiseDavid robertsMichael sarconeMichael petuskyMartha shadanScott henryPurnima malikJames sidotiCompany participants

Why Co-Diagnostics Stock Slipped Today

Investors continued to avoid the company after its big second-quarter whiffs.

James sidoti

vimarsana © 2020. All Rights Reserved.